Lessons from immuno-oncology: A new era for cancer nanomedicine?

Wen Jiang, Hengfeng Yuan, Charles K. Chan, Christina A. Von Roemeling, Zuoqin Yan, Irving L. Weissman, Betty Y.S. Kim

Research output: Contribution to journalReview article

18 Scopus citations

Abstract

Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.

Original languageEnglish (US)
Pages (from-to)369-370
Number of pages2
JournalNature Reviews Drug Discovery
Volume16
Issue number6
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Lessons from immuno-oncology: A new era for cancer nanomedicine?'. Together they form a unique fingerprint.

  • Cite this

    Jiang, W., Yuan, H., Chan, C. K., Von Roemeling, C. A., Yan, Z., Weissman, I. L., & Kim, B. Y. S. (2017). Lessons from immuno-oncology: A new era for cancer nanomedicine? Nature Reviews Drug Discovery, 16(6), 369-370. https://doi.org/10.1038/nrd.2017.34